<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078619</url>
  </required_header>
  <id_info>
    <org_study_id>NL77915.041.21</org_study_id>
    <nct_id>NCT05078619</nct_id>
  </id_info>
  <brief_title>Percutaneous Coronary Intervention Before Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>PRO-TAVI</acronym>
  <official_title>Percutaneous Coronary Intervention Before Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the safety and cost effectiveness of omission of&#xD;
      percutaneous coronary intervention of significant coronary artery disease in patients&#xD;
      scheduled to undergo transcatheter aortic valve implantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2021</start_date>
  <completion_date type="Anticipated">August 22, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite of all-cause mortality, myocardial infarction, stroke and major bleeding</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>4 months - 12 months - total follow up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>4 months - 12 months - total follow up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>4 months - 12 months - total follow up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
    <time_frame>4 months - 12 months - total follow up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minor bleeding</measure>
    <time_frame>4 months - 12 months - total follow up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urgent and elective revascularization</measure>
    <time_frame>4 months - 12 months - total follow up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalization</measure>
    <time_frame>4 months - 12 months - total follow up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function measured by echocardiography</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of omission of PCI using QALYs</measure>
    <time_frame>4 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of omission of PCI using Incremental Cost Effectiveness Ratios</measure>
    <time_frame>4 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Euro Quality of Life 5D Questionnaire</measure>
    <time_frame>4 months - 12 months</time_frame>
    <description>the system produces a 5-digit health status profile to describe quality of life in a descriptive manner. Therefore, no lowest and highest value can be stated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by SF-36 Questionnaire</measure>
    <time_frame>4 months - 12 months</time_frame>
    <description>Questionnaire consists of eight sections. Each section is transformed into a 0 - 100 scale. The lower the score the more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anginal status assessed by CCS classification</measure>
    <time_frame>4 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anginal status assessed by Seattle Angina Questionnaire</measure>
    <time_frame>4 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anginal status assessed by NYHA classification</measure>
    <time_frame>4 months - 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">466</enrollment>
  <condition>Valvular Heart Disease</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>TAVI only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomly allocated to this study arm will undergo transcatheter aortic valve implantation without preceding PCI of significant coronary artery disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI with preceding PCI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomly allocated to this study arm will undergo transcatheter aortic valve implantation with preceding PCI of significant coronary artery disease which is currently the standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No PCI</intervention_name>
    <description>Omission of PCI of significant coronary artery disease prior to TAVI</description>
    <arm_group_label>TAVI only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe AoS meeting the criteria stated by the ESC in the ESC/EACTS Guidelines for the&#xD;
             management of valvular heart disease AND considered symptomatic (NYHA functional class&#xD;
             ≥ 2);&#xD;
&#xD;
          -  TAVI decided by multidisciplinary Heart Team taken into account the international&#xD;
             standards by ESC and guidelines of Dutch Society for Cardiology (NVVC);&#xD;
&#xD;
          -  ≥ 1 stenosis in epicardial coronary artery (&gt; 2.5mm) or bypass graft. Stenosis is&#xD;
             considered significant if angiographic 70-99% or angiographic 40-70% with positive&#xD;
             hemodynamic parameters.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  LM-stenosis or equivalent&#xD;
&#xD;
          -  CAD with patent bypass grafts&#xD;
&#xD;
          -  Contraindication for DAPT&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiel Voskuil, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michiel Voskuil, MD PhD</last_name>
    <phone>+31 (0)88 75 561 67</phone>
    <email>mvoskuil@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RadboudUMC</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Niels van Royen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis Breda</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis Den Haag</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Joanna Wykrzykowska</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Michiel Voskuil, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>Transcatheter aortic valve implantation</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

